 DARTMOUTH, Nova Scotia CAMBRIDGE, Mass.--BUSINESS WIRE--IMV Inc. Nasdaq: IMV; TSX: IMV, a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, today announced that it is hosting a Research and Development Day via webcast on Thursday, February 24, 2022 at 8:00am Eastern Time to highlight the differentiating features of its patented DPX delivery platform. IMVs DPX technology is a delivery plat 